autoimmune disease

Pharma

Roche's Enspryng muscles in on Tepezza's TED turf

Some six years after scoring an initial FDA nod, Roche’s IL-6 receptor inhibitor Enspryng is muscling up to Amgen's Tepezza in a key eye disease arena.

Fraiser Kansteiner Oct 16, 2026 9:26am

Argenx calls it quits on Vyvgart Hytrulo Sjögren's disease trial

Oct 8, 2026 10:44am

pivot change turnaround direction walk away

Roche's Gazyva secures FDA nod in 2nd autoimmune indication

Sep 28, 2026 2:29pm

Priovant secures 1st FDA nod in rare skin and muscle disease

Aug 27, 2026 9:30pm

Argenx preps next potential Vyvgart nod after ph. 3 win

Aug 17, 2026 10:52am

photo of a pair of hands that show the skin condition vitiligo

Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie

Jul 30, 2026 2:15pm